EGFR and non-small cell lung carcinoma: The FLAURA2 trial showed that the addition of chemotherapy to osimertinib resulted in a significant improvement in therapeutic efficacy for EGFR-mutated NSCLC, making this combination a promising option for first-line treatment50.